Summary | Art by Mike LucasIn this morning's Web roundup,
AstraZeneca PLC's $4 billion purchase of cancer-drug startup
Acerta Pharma B.V. is a win for early investor BioGeneration
Ventures. Hampton Creek Inc. received approval from the U.S.
Food and Drug Administration to continue calling its flagship
product "Just Mayo." And Navitor Pharmaceuticals Inc. has ...
AstraZeneca PLC's $4 billion purchase of cancer-drug startup
Acerta Pharma B.V. is a win for early investor BioGeneration
Ventures. Hampton Creek Inc. received approval from the U.S.
Food and Drug Administration to continue calling its flagship
product "Just Mayo." And Navitor Pharmaceuticals Inc. has ...
blogs.wsj.com | 18 December 2015